Moleculin Biotech, Inc. (MBRX)
| Market Cap | 8.61M -44.1% |
| Revenue (ttm) | n/a |
| Net Income | -32.53M |
| EPS | -9.60 |
| Shares Out | 19.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 342,527 |
| Open | 0.4199 |
| Previous Close | 0.4240 |
| Day's Range | 0.4127 - 0.4564 |
| 52-Week Range | 0.1614 - 15.7500 |
| Beta | 2.00 |
| Analysts | Strong Buy |
| Price Target | 12.00 (+2,614.93%) |
| Est. Earnings | Nov 12, 2026 |
About MBRX
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for MBRX stock is "Strong Buy." The 12-month stock price target is $12.0, which is an increase of 2,614.93% from the latest price.
News
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
HOUSTON, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it will present at the upcoming 2026 Maxim Growth Summit in New Yo...
Moleculin Biotech completes enrollment in Part A of Phase 2/3 R/R MIRACLE trial
Moleculin Biotech (MBRX) announced that it has completed and closed enrollment in Part A of its Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine for the treatment of…
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
HOUSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it has completed and closed enrollment in Part A of its pivotal P...
Moleculin Biotech announces publication of analysis of Annamycin in Frontiers
Moleculin Biotech (MBRX) announced the publication of a peer-reviewed analysis of the cardiac safety of Annamycin in Frontiers in Cardiovascular Medicine. The publication, titled “Cardiac safety of L-...
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
– Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits
Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR
Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin's antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-mediated mechanism alongside its...
Moleculin Biotech secures Mexican patent protecting Annamycin through 2040
Moleculin Biotech (MBRX) announced that the Mexican Patent Office has granted Patent No. 436849, further strengthening the Company’s global intellectual property portfolio protecting its proprietary l...
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
Strengthens Global Intellectual Property Estate for Annamycin's Proprietary Liposomal Formulation Designed to Target Lung Metastases While Supporting Long-Term Commercial Opportunity
Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings
Presentations examine where Annamycin concentrates in the body, how it targets topoisomerase II, and its antitumor activity in pancreatic cancer
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand
HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that its pre-recorded presentation from the H.C. Wainwright 28th Ann...
Moleculin Biotech Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Annamycin, a non-cardiotoxic anthracycline, is showing strong efficacy and safety in a pivotal phase III AML trial, with remission rates three times higher than control and no cardiotoxicity. The drug targets a multi-billion-dollar market, with broad potential beyond AML and strong support from physicians and payers.
Moleculin Biotech price target lowered to $3 from $22 at H.C. Wainwright
H.C. Wainwright analyst Sara Nik lowered the firm’s price target on Moleculin Biotech (MBRX) to $3 from $22. The firm cites the company’s expansion in fully diluted shares outstanding to…
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference
- Video webcast now available here
Moleculin Biotech Proxy statement: Proxy filing
Moleculin Biotech filed a proxy statement on August 24, 2026, providing details for shareholder voting and corporate governance matters.
Moleculin Biotech Proxy statement: Proxy filing
Moleculin Biotech filed a proxy statement on August 24, 2026, providing details for shareholder voting and corporate governance matters.
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial
Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AML MIRACLE trial advancing toward planned 90-patient enrollment milestone in Septe...
Moleculin Biotech Proxy statement: Proxy filing
Moleculin Biotech filed a proxy statement on August 14, 2026, providing details for shareholder voting and corporate governance matters.
Moleculin Biotech Quarterly report: Q2 2026
Moleculin Biotech has published its Q2 2026 quarterly earnings report on August 13, 2026.
Moleculin Biotech Earnings release: Q2 2026
Moleculin Biotech released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Moleculin Biotech Slides: Corporate presentation
Moleculin Biotech has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Moleculin Announces Pricing of $9.3 Million Public Offering
HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced the pricing of a best-efforts public offering of an aggregate of 12,3...
Moleculin Biotech updates preliminary blinded results from MIRACLE trial Part A
Moleculin Biotech (MBRX) announced updated preliminary blinded results from Part A of its pivotal Phase 2/3 MIRACLE trial of Annamycin in combination with cytarabine for the treatment of relapsed or…
Moleculin's MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
Prior venetoclax failure — a setting in which published salvage remission rates are approximately 13% and median survival approximately 2.4 months — shows no adverse impact on blinded composite remiss...
Moleculin Biotech Registration statement: Registration filing
Moleculin Biotech filed a registration statement on July 31, 2026, providing details about a securities offering with the SEC.
Moleculin Biotech Registration statement: Registration filing
Moleculin Biotech filed a registration statement on July 30, 2026, providing details about a securities offering with the SEC.